Thoracic Malignancies

Ohio State University   

Ohio State University Tumor Boards

Questions discussed in this category



Ex. TP53, BRCA, T790M, or another? As of now, T790M mutation is one of the few de novo mutations found in treatment naïve patients that have been...

Patient has been on pembrolizumab and had two symptomatic soft tissue mass treated with radiation. 

Would you consider afatinib? Afatinib has shown some activity in NRG1 fusion + patients but amplifications is unclear. 

Are there any data to support a specific TKI therapy for non-T790M exon 20 mutations/insertions?

Would you treated with local therapies (RFA or SRS) and continue pembrolizumab or would you move to second line treatment?

Especially if you don't have trials available at the moment. Would you try off-label erdafitinib (given recent data on bladder cancer) or 2nd line ge...

In the absence of a frontline clinical trial, would you treat with carboplatin+pemetrexed+pembrolizumab or consider IMPOWER 150 or other?

In a patient with lung cancer with both NSCLC and SCLC components, would you offer carbo/pem/pembro or carbo/etoposide/atezolizumab? Or any other alte...

The NCCN guidelines regard  MET exon 14 skip mutation   as an emerging biomarker but no formal recommendation to start crizotinib. If high P...

Given the potential high risk of developing pneumonitis with TKI post checkpoint inhibitor, do you avoid TKIs and try a different regimen (ex carbo/pa...

Retrospective data suggest clinically significant disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung canc...

No other site of metastatic disease. It is unclear if this situation should be managed as two separate primaries or metastatic disease.

Carbo/pemetrexed/pembrolizumab, carbo/pemtrexed without immunotherapy or second line immunotherapy (Nivo, Pem or atezolizumab)?

PD-L1 < 50% and no targetable mutations. Would you use carbo/pemetrexed/pembrolizumab or Nivolumab or pembrolizumab?

Lung primary is inaccessible for biopsy and metastatic sites are only 2 small bone lesions. In a non-smoker, a driver mutation is suspected but would ...

Certainly ovarian cancer will respond to carboplatin and paclitaxel and it sounds like a reasonable chemotherapy to give to a stage IV NSCLC, however ...


Papers discussed in this category


Science translational medicine, 2013-12-18

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-02

Annals of internal medicine, 2018-01-16

Cancer Discov,

Clin. Cancer Res.,

N. Engl. J. Med.,

J Thorac Oncol, 2018 Feb

The New England journal of medicine, 2018-06-14

The New England journal of medicine, 2016-11-10

The New England journal of medicine, 2018-05-31

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-03-01

J. Clin. Oncol., 2017 Oct 02

N. Engl. J. Med., 2017 Jun 04

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-04-15

The New England journal of medicine, 2018-01-11

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019-08-01

Nat Commun, 2019 Mar 27

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01

Cancer, 2005-04-15

Lung cancer (Amsterdam, Netherlands), 2015-12

Nature medicine, 2018-05

Cancer, 2017-11-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-08-20

Lancet (London, England), 2019-05-04

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-07

European journal of cancer (Oxford, England : 1990), 2019-03

Lancet Oncol, 2019 May 20

Lung Cancer, 2012 Feb 10

JAMA, 2014-05-21

Clin. Cancer Res., 2019 Aug 15

Ann. Oncol.,

Cancer discovery, 2015-08

Annals of oncology : official journal of the European Society for Medical Oncology, 2018-10-01

Nature, 2014-07-31

Cancer discovery, 2015-08

Lancet Oncol.,

The New England journal of medicine, 2016-03-03

Cancer immunology, immunotherapy : CII, 2017-01

Cancer, 2017-06-01

Journal of the American Academy of Dermatology, 2019-07-11

J Immunother,

Oncologist, 2020 Feb 11

The New England journal of medicine, 2018-12-06

Lancet, 2019 Oct 04

Ann Oncol, 2019 Oct 1

Int J Cancer, 2020 Dec 21

Adv Ther, 2020 Oct 29

Ann Oncol, 2022 Feb 14